Publications
(2024)
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Commun Chem. 7, 38
(2024) Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Commun Chem. 7, 38
(2024) Mechanisms of amphibian arrestin 1 self-association and dynamic distribution in retinal photoreceptors. J Biol Chem. 300, 107966
(2024) Modulating the pH dependent photophysical properties of green fluorescent protein. RSC Adv. 14, 32284-32291
(2024) Modulating the pH dependent photophysical properties of green fluorescent protein. RSC Adv. 14, 32284-32291
(2024) Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality. ACS Cent Sci. 10, 1156-1166
(2024) (2024) Noncovalent Inhibition and Covalent Inactivation of Proline Dehydrogenase by Analogs of -Propargylglycine. Biochemistry. 63, 2855-2867
(2024) Noncovalent Inhibition and Covalent Inactivation of Proline Dehydrogenase by Analogs of -Propargylglycine. Biochemistry. 63, 2855-2867
(2024) Noncovalent Inhibition and Covalent Inactivation of Proline Dehydrogenase by Analogs of -Propargylglycine. Biochemistry. 63, 2855-2867
(2024) Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε.. J Med Chem. 67, 8609-8629
(2024) Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques. Cell. 187, 7214-7231.e23
(2024) Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques. Cell. 187, 7214-7231.e23
(2024) Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques. Cell. 187, 7214-7231.e23
(2024) A potential role for RNA aminoacylation prior to its role in peptide synthesis. Proc Natl Acad Sci U S A. 121, e2410206121
(2024) POTRA domains of the TamA insertase interact with the outer membrane and modulate membrane properties. Proc Natl Acad Sci U S A. 121, e2402543121
(2024) POTRA domains of the TamA insertase interact with the outer membrane and modulate membrane properties. Proc Natl Acad Sci U S A. 121, e2402543121
(2024) Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. Cell. 187, 4305-4317.e18
(2024) Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. Cell. 187, 4305-4317.e18
(2024) Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. Cell. 187, 4305-4317.e18
(2024) Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. Cell. 187, 4305-4317.e18
(2024) Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. Cell. 187, 4305-4317.e18
(2024) (2024) (2024)